A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2023-03-07 / Cancer Immunol Immunother 2023 Mar;Current „state of the art“ on dendritic cell-based cancer vaccines in melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-93Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models
/in Colorectal Cancer, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2022-07-07 / Cancer Res Commun 2022 Jul;2(7):602-615Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-01 / Melanoma Res 2021 Aug;31(4):378-388Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2021-07-19 / Sci Rep 2021 Jul;11(1):14661A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-1986Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
/in Dendritic Cells, International Publications, Malignant Melanoma, Malignant Pleural Mesothelioma /von 2021-05-19 / Vaccines (Basel) 2021 May;9(5)Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-05-12 / Cancer Med 2021 Jul;10(13):4302-4311
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de